CD8A and neoplasm: We evaluated the HPV antigen-specific CD8+ T cell-mediated immune responses as well as therapeutic anti-tumor effects in TC-1 tumor-bearing female C57BL/6 mice treated with pBI-11 DNA vaccination using three different delivery methods: (i) I.M. with a conventional needle and syringe, (ii) I.M. with a customized needle-free biojector, or (iii) I.D. with a customized needle-free biojector.